Related Experiment Video
Updated: Apr 25, 2026
05:52
Sentinel Lymph Node Mapping and Biopsy for Endometrial Cancer at Early Stage with Laparoscopy
Published on: August 19, 2021
13.7K
[Uterine sarcoma in Tunisia: retrospective study about 14 cases]
N Bouzid1, S Kanoun Belajouza1, H Boussen2
1Service de cancérologie-radiothérapie, CHU Farhat Hached de Sousse, Sousse, Tunisie.
Gynecologie, Obstetrique & Fertilite
|August 27, 2014
Summary
Uterine sarcomas are rare and aggressive cancers. Adjuvant therapies like radiotherapy and chemotherapy are crucial for managing uterine sarcoma recurrence and improving patient outcomes.
Area of Science:
- Gynecologic Oncology
- Medical Imaging
- Radiation Oncology
Background:
- Uterine sarcoma (US) is a rare gynecologic malignancy.
- This study focuses on a Tunisian cohort to describe US epidemiology, treatment, and outcomes.
Observation:
- A retrospective analysis of 14 US cases (1995-2008) including leiomyosarcoma, mixed Mullerian tumors, and endometrial stromal sarcoma.
- Diagnosis was often postoperative or post-curettage; FIGO staging revealed 8 in Stage I, 3 in Stage II, and 3 in Stage III.
- Treatment involved hysterectomy with annexectomy in most cases, with limited pelvic lymphadenectomy.
Findings:
- Four patients who did not receive adjuvant therapy experienced recurrence, with metastases in two cases.
- Of 14 patients, 7 remained disease-free after a median follow-up of 54 months, while 5 died from the disease.
- Adjuvant radiotherapy was given to 8 patients, with chemotherapy in 3, showing potential benefit in disease control.
Implications:
- Uterine sarcomas present a poor prognosis, underscoring the need for timely and effective treatment strategies.
- Adjuvant radiotherapy and chemotherapy should be considered to mitigate the high risk of recurrence and metastasis in uterine sarcoma patients.
- Further research into optimal adjuvant treatment protocols for uterine sarcoma is warranted.
